Skip to main content
Uncategorized

Oryzon Licenses Human Antibody Phage Display Technology for Discovery of Novel Therapeutics

By 15 de November de 2010November 18th, 2020No Comments
< Back to news
 15.11.2010

Oryzon Licenses Human Antibody Phage Display Technology for Discovery of Novel Therapeutics

Oryzon has signed a non-exclusive license with Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, to develop therapeutic antibody products using Dyax's proprietary technology, phage display. This Agreement grants Oryzon a non-exclusive license to use Dyax's human antibody libraries to discover antibodies and the right to commercially develop such antibody products.

Under this agreement with Oryzon, Dyax Corp. will receive an undisclosed upfront fee and development milestones as well as royalties and sales milestones for each antibody product commercialized by Oryzon using Dyax’s technology. Dyax will also receive a percent of Oryzon’s sublicensing income if Oryzon licenses one of these antibody products to a third party.

Carlos Buesa CEO and Chairman of ORYZON has declared: “Our partnership with Dyax is a fundamental step to position Oryzon definitively in the therapeutic monoclonal antibody arena with the best partner”. With this agreement Oryzon becomes the first Spanish Biopharma company committed to developing therapeutic antibody products.

Oryzon was founded in 2000 as a spin-off of the University of Barcelona and CSIC. Today, with an international interdisciplinary team of 70 employees, Oryzon is recognized as the leading biomarker discovery company in Spain. Oryzon has a complementary diagnostic and therapeutic pipeline focusing on oncology and neurodegeneration.